

EUROPEAN  
CURRICULUM VITAE  
FORMAT



PERSONAL INFORMATION

Name PINA ZIRANU  
Institutional Address  
Telephone  
Fax  
E-mail

Nationality  
Date of birth

STUDIES APPLIED FOR MEDICAL ONCOLOGIST

WORK EXPERIENCE

- 01/12/2017 – currently **Oncology Consultant**  
*Medical Oncology Unit, University Hospital and University of Cagliari, Italy*  
S.S. 554 - km 4,500 Bivio per Sestu, 09042 Monserrato (Italy).  
Chief: Prof. Mario Scartozzi
- 01/07/2017 – 31/11/2017 **Medical Oncologist**  
*Medical Oncology Unit, University Hospital and University of Cagliari, Italy*  
Oncology fellowship "Prospective validation models for prognostic and predictive factors in patients with gastrointestinal tumours" at Medical Oncology Unit, University Hospital and University of Cagliari, Italy. Scientific Manager: Prof. Mario Scartozzi
- 20/03/2016 – 28/02/2017 **Medical Oncologist**  
*Medical Oncology Unit, University Hospital and University of Cagliari, Italy*  
Oncology fellowship "Multidisciplinary management of patients with the head and neck cancer and clinical and translational trial into 'Division of Medical Oncology'" at Medical Oncology Unit, University Hospital and University of Cagliari, Italy.  
Scientific Manager: Prof. Mario Scartozzi
- 23/06/2016 – 30/09/2017 **Integrated Home Care Assistance Coordinator**  
*Cooperative OSAT, Quartu Sant'Elena (Italy)*  
Integrated Home Care Assistance Coordinator for HIV / AIDS patients and related diseases (cancer and opportunistic infections)
- 23/06/2016 – 08/01/2017 **Acting Director – Hospice Madonna di Fatima**  
*Cooperative OSAT, Quartu Sant'Elena (Italy)*  
Acting Director Hospice Madonna di Fatima, Residential Center for palliative care, Loc. Sa Tiaca, Quartu Sant'Elena

• 01/07/2015 – 11/09/2016

**Medical Oncologist**

*Cooperative OSAT, Quartu Sant'Elena (Italy)*

Medical Oncologist at Hospice Madonna di Fatima, Residential Center for palliative care, Loc. Sa Tiaca, Quartu Sant'Elena

• 01/07/2015 – 11/09/2016

**Medical Oncologist**

*Cooperative OSAT, Quartu Sant'Elena (Italy)*

Medical Oncologist at Integrated Home Care Assistance for HIV / AIDS patients and related diseases (cancer and opportunistic infections)

• 15/09/2014 – 17/05/2015

**Resident in Medical Oncology**

Internship at Medical Oncology Department - Niguarda Cancer Center - Grande Ospedale Metropolitano Niguarda, Milano (Italia). On the behalf of Medical Oncology Residency - University of Cagliari

Supervisor: Prof S. Siena; Residency Director: Prof M. Scartozzi

• 17/05/2010 – 17/05/2015

**Resident in Medical Oncology**

Medical Oncology Unit, University Hospital and University of Cagliari, Italy.

Residency Director: Prof. M. Scartozzi

• Main activities and responsibilities

Management of outpatients and inpatients. Collection of medical record, clinical examination and global evaluation of patients with solid tumors, focusing on comorbidities, concomitant therapies and patients' will. Evaluation of imaging diagnostic tests. Diagnostic and therapeutic decision making according to guidelines and communication of cancer diagnosis to patients and their relatives. Laboratory tests check preliminary to chemotherapy administration, management of toxicities of cytotoxic drugs, monoclonal antibodies, immunotherapy, infusion and hypersensitivity reactions. Management of follow up and after hospital discharge. Management of cancer patient symptoms and needs. Simultaneous care; palliative care and end-of-life care for terminally ill patients. Screening and prevention programs for patients and their relatives. Early detection and treatment of cancer pain and oncological emergencies.

Laboratory skills: preparation of biological samples for central laboratories of clinical trials. Centrifuge use. Preparation of blood samples for circulating-tumor DNA analysis (liquid biopsy). Elisa assay.

Excellent communication skills, conflict resolution and decision making. Responsible, loyal and discreet; able to maintain strict levels of confidentiality in handling sensitive information. Able to build relationships and devoted to teamwork. Good leadership skills. Solid organizational skills: ability to multi-task, coordinate multiple projects simultaneously and meet deadlines under stringent time constraints. Good skills in scientific events planning. Active member of multidisciplinary groups on gastrointestinal cancer. Organization of hospital access and discharge of cancer patients for antineoplastic treatment and supportive care, therapeutic program and follow up. Supervisor of Medical Students and responsible for work schedule of Medical Oncology Residents.

Sub-investigator of several national and international ongoing clinical trials (phase II-IV) according to GCP at Medical Oncology Unit of Cagliari University Hospital on clinical and translational research since Post-graduate School in Medical Oncology at Cagliari University Hospital. Experience in design and management of clinical trials according to Good Clinical Practice, interpretation of experimental data, presentation of clinical trials and reviews on national and international scientific journals. Involvement in clinical and translational research focused on predictive and prognostic factors for gastrointestinal tumors.

**EDUCATION AND TRAINING**

2015

**Post-Graduate Degree in Medical Oncology**

Medical Oncology Residency - University of Cagliari, Cagliari (Italy)

Grade: 50/50 cum laude. Experimental Thesis: "Tumor *MGMT* promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer" Prof M. Scartozzi Supervisor: Prof S. Siena

2008

**Degree in Medicine and Surgery University of Cagliari, Cagliari, Italy.**  
Grade: 110/110 cum laude. Experimental thesis: "Efficacy and safety of irinotecan-based regimen plus bevacizumab in metastatic colorectal cancer" Supervisor: Prof B. Massidda

2000

**High School Diploma**  
Liceo Scientifico "Enrico Fermi", Nuoro (Italia)

**MOTHER TONGUE**

**ITALIAN**

**OTHER LANGUAGE**

**ENGLISH**

Understanding: Listening B2, Reading B2; Speaking: Spoken interaction B1, Spoken production B1; Writing B2.

**MEMBERSHIP**

AIOM (dal 2008)  
ESMO (dal 2013)

**ADDITIONAL INFORMATION**

**Scientific Publication Peer  
Reviewed Journals with impact  
factor**

1. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. Demurtas L, Puzzoni M, Giampieri R, **Ziranu P**, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M *British Journal of Cancer* (2017), 1–7. doi: 10.1038/bjc.2017.178

2. Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance? Ziranu P, Atzori F, Puzzoni M, Demurtas L, Astaro G and Scartozzi M. *TCR 2017-111. Translational cancer research* 2017. doi: 10.21037/tcr.2017.07.01.

3. BRAF-mutant colorectal cancer, a different breed evolving. Lai E, Pretta A, Impera V, Mariani S, Giampieri R, Casula L, Pusceddu V, Coni P, Fanni D, Puzzoni M, Demurtas L, **Ziranu P**, Faa G & Scartozzi M (2018): *Expert Review of Molecular Diagnostics*, DOI:10.1080/14737159.2018.1470928

4. Prognostic value of thyroid hormones ratio in advanced metastatic colorectal cancer patients treated with regorafenib: the TOREADOR study. Schirripa M, Pasqualetti G, Giampieri R, Scartozzi M, Lonardi S, Ruman L, Bergamo F, Stragliotto S, Murgioni S, Alberti G, Rizzato MD, Prete AA, Puzzoni M, Pusceddu V, **Ziranu P**, Pani F, Mariotti S, Zagonel V, Monzani F, Loupakis F. *Clin Colorectal Cancer*. 2018 Sep;17(3):e601-e615. doi: 10.1016/j.clcc.2018.05.013. Epub 2018 Jun 8.

5. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, **Ziranu P**, Schirripa M, Buggin F, Prete AA, Depetris I, Bion P, Lonardi S, Zagonel V, Fassan M, Di Maio M *Eur J Cancer*. 2019 Jul 19;118:121-130. doi: 10.1016/j.ejca.2019.06.008.

6. Clustered protocadherins methylation alterations in cancer. Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, Arcella A, Badiali M, Giangaspero F, Morra I, Columbano A, Restivo A, Zorcolo L, Gismondi V, Varesco L, Bellomo SE, Giordano S, Canale M, Casadei-Gardini A, Faloppi L, Puzzoni M, Scartozzi M, **Ziranu P**, Cabras G, Cocco P, Ennas MG, Satta G, Zucca M, Canzio D, Zavattari P. *Clin Epigenetics*. 2019 Jul 9;11(1):100. doi: 10.1186/s13148-019-0695-0.

7. Gastric cancer: Translating novel concepts into clinical practice. Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, **Ziranu P**, Cascinu S. *Cancer Treat Rev.* 2019 Sep;79:101889. doi: 10.1016/j.ctrv.2019.101889.
8. New therapeutic targets in pancreatic cancer. Lai E, Puzzone M, **Ziranu P**, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. *Cancer Treat Rev.* 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926.
9. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? Puzzone M, **Ziranu P**, Demurtas L, Lai E, Mariani S, Liscia N, Soro P, Pretta A, Impera V, Camera S, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Scartozzi M. *Future Oncol.* 2020 Jan;16(2):4337-4339. doi: 10.2217/fon-2019-0624. Epub 2019 Dec
10. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. L. Faloppi, M. Puzzone, A. Casadei Gardini, N. Silvestris, G. Masi, G. Marisi, C. Vivaldi, C.D. Gadaleta, **P. Ziranu**, M. Bianconi, C. Loretelli, L. Demurtas, E. Lai, R. Giampieri, E. Galizia, P. Ulivi, N. Battelli, A. Falcone, S. Cascinu, Scartozzi M *Target Oncol.* 2020 Feb;15(1):115-126. doi: 10.1007/s11523-020-00698-x. PMID: 32020517
11. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. E. Lai, N. Liscia, C. Donisi, S. Mariani, S. Tolu, A. Pretta, M. Persano, G. Pinna, F. Balconi, A. Pireddu, V. Impera, M. Dubois, M. Migliari, D. Spanu, G. Saba, S. Camera, F. Musio, **P. Ziranu**, M. Puzzone, L. Demurtas, V. Pusceddu, M. Dettori, E. Massa, F. Atzori, M. Dessì, G. Astara, C. Madeddu, M. Scartozzi. *Cancers (Basel).* 2020 May 13;12(5):E1214. doi: 10.3390/cancers12051214.
12. From CENTRAL to SENTRAL (SErum aNGiogenesis ceNTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. R. Giampieri, **P. Ziranu**, B. Daniele, A. Zizzi, D. Ferrari, S. Lonardi, A. Zaniboni, L. Cavanna, G. Rosati, M. Casagrande, N. Pella, L. Demurtas, MG Zampino, P. Sozzi, V. Pusceddu, D. Germano, E. Lai, V. Zagonel, C. Codecà, M. Libertini, M. Puzzone, R. Labianca, S. Cascinu, M. Scartozzi. *Cancers (Basel).* 2020 May 22;12(5):E1330. doi: 10.3390/cancers12051330. PMID: 32456056
13. Fluoropyrimidine Single Agent or Doublet Chemotherapy as Second Line Treatment in Advanced Biliary Tract Cancer. C. Neuzillet, A. Casadei-Gardini, B. Briau, C. Vivaldi, G. Brandi, D. Tougeron, R. Filippi, A. Vienot, N. Silvestris, A.L. Pointet, S. Lonardi, B. Rousseau, M. Scartozzi, L. Dahan, G. Aprile, S.L. Sourd, L. Evesque, A. Meurisse, A. Lièvre, D. Vernerey; AGEO (Association des Gastro-Entérologues Oncologues) and GICO (Italian Group of Cholangiocarcinoma) investigators (T. Boussaha, A. Heurgué, J. Desramé, T. Lecomte, W. Cacheux, J.-B. Bachet, J.-M. Phelip, V. Hautefeuille, N. Hammoudi, F. Mary, C. Locher, A. Bidault-Thirot, L. Marthey, Y. Toucheffeu, V. Moulin, A. Zaanani, J. Taïeb, M. Casagrande, S. Murgioni, D. Santini, L. Fornaro, F. Montagnani, F. Leone, L. Faloppi, E. Giommoni, S. Eufemia Lutrino, A. Palloni, O. Brunetti, A. Argentiero, F. Bergamo, E. Vasile, E. Lai, M. Puzzone, **P. Ziranu**, V. Dadduzio, M. Rizzato, A. Pellino, M. Aglietta, A. Cappetta, S.K. Garattini, D. Basile) *Int J Cancer.* 2020 Jun 11. doi: 10.1002/ijc.33146.
14. Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. A.F. Vega-Benedetti, E. Loi, L. Moi, S. Orrù, **P. Ziranu**, A. Pretta, E. Lai, M. Puzzone, L. Ciccone, A. Casadei-Gardini, F. Cabras, F. Fortunato, A. Restivo, L. Zorcolo, M. Scartozzi, P. Zavattari *Int J Mol Sci.* 2020 Jun 24;21(12):E4494. doi: 10.3390/ijms21124494.
15. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. Pasqualetti G, Schirripa M, Dochy E, Fassan M, **Ziranu P**, Puzzone M, Scartozzi M, Alberti G, Lonardi S, Zagonel V, Monzani F, Loupakis F. *European Journal of Cancer.* Vol 133, July 2020, pages 66-73

16. Retrospective survival analysis in metastatic pancreatic ductal adenocarcinoma patients with insulin-treated type 2 Diabetes Mellitus. A.Pretta, **P. Ziranu**, M. Puzzone, E. Lai, G. Orsi, N. Liscia, E. Molinaro, S. Mariani, L. Riggi, G. Rovesti, M. Dubois, M. Migliari, M. Persano, G. Saba, V. Impera, F. Musio, E. Batzella, L. Demurtas, V. Pusceddu, G. Astara, L. Faloppi, A. Casadei Gardini, K. Andrikou, S. Cascinu, Scartozzi M. *Tumori*. 2020 Nov 26;300891620976945. doi: 10.1177/0300891620976945.
17. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? E. Lai, G. Astara, **P. Ziranu**, A. Pretta, M. Migliari, M. Dubois, C. Donisi, S. Mariani, N. Liscia, V. Impera, M. Persano, S. Tolu, F. Balconi, G. Pinna, D. Spanu, A. Pireddu, G. Saba, S. Camera, F. Musio, M. Puzzone, V. Pusceddu, C. Madeddu, A. Casadei Gardini, M. Scartozzi. *Crit Rev Oncol Hematol*. 2021 Jan;157:103167. doi: 10.1016/j.critrevonc.2020.103167. Epub 2020 Nov 12. PMID: 33271389
18. Immune checkpoint Inhibitors in the treatment of HCC. C. Donisi, M.Puzzone, **P.Ziranu**, E. Lai, S. Mariani, G. Saba, V. Impera, M. Dubois, M. Persano, M. Migliari, A. Pretta, N. Liscia, G. Astara, M. Scartozzi. *Front Oncol*. 2021 Jan 7;10:601240. doi: 10.3389/fonc.2020.601240. PMID: 33585218
19. Combining Immunotherapy with Anti-angiogenic Therapy: The New Standard of Care for Hepatocellular Cancer? Dubois M, Persano M, Balconi F, Donisi C, Impera V, Liscia N, Mariani S, Migliari M, Musio F, Pinna G, Pireddu AG, Pretta A, Saba G, Spanu D, Tolu S, Demurtas L, Puzzone M, **Ziranu P**, Lai E, Astara G\* and Scartozzi M ? *J Clin Oncol Ther*, Volume 3:1. 117. DOI: <https://doi.org/10.47275/2690-5663-117>
20. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. **Ziranu P**, Lai E, Schirripa M, Puzzone M, Persano M, Pretta A, Munari G, Liscia N, Pusceddu V, Loupakis F, Demurtas L, Libertini M, Mariani S, Migliari M, Dubois M, Giampieri R, Sotgiu G, Dei Tos AP, Lonardi S, Zaniboni A, Fassan M, Scartozzi M. *Target Oncol*. 2021 May 10. doi: 10.1007/s11523-021-00816-3. Epub ahead of print. PMID: 33970400.
21. BRCA-mutant pancreatic ductal adenocarcinoma. Lai E, **Ziranu P**, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzone M, Scartozzi M. *Br J Cancer*. 2021 Jul 14. doi: 10.1038/s41416-021-01469-9.
22. Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Lai E, Puzzone M, **Ziranu P**, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccacino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M. Long term survival with regorafenib: *Clin Colorectal Cancer*. 2021 Jul 31:S1533-0028(21)00073-6. doi: 10.1016/j.clcc.2021.07.008. Online ahead of print.
23. Molecular-driven treatment for biliary tract cancer: the promising turning point. Persano M, Puzzone M, **Ziranu P**, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M. *Expert Rev Anticancer Ther*. 2021 Sep 24:1-12. doi: 10.1080/14737140.2021.1982699. Epub ahead of print. PMID: 34551663.
24. Giampieri R, Lupi A, **Ziranu P**, Bittoni A, Pretta A, Pecci F, Persano M, Giglio E, Copparoni C, Crocetti S, Mandolesi A, Faa G, Coni P, Scartozzi M, Berardi R. Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. *Front Oncol*. 2021 Sep 30;11:736104. doi: 10.3389/fonc.2021.736104. eCollection 2021.
25. Vega-Benedetti AF, Loi E, Moi L, Restivo A, Cabras F, Deidda S, Pretta A, **Ziranu P**, Orrù S, Scartozzi M, Zorcolo L, Zavattari P. Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue. *Hum Cell*. 2022 Jan;35(1):310-319.

26. Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, **Ziranu P**, Scartozzi M. Uncovering key targets of success for immunotherapy in pancreatic cancer. *Expert Opin Ther Targets*. 2021 Nov;25(11):987-1005. doi: 10.1080/14728222.2021.2010044. Epub 2021 Dec 13. PMID: 34806517.
27. Loi E, Zavattari C, Tommasi A, Moi L, Canale M, Po A, Sabato C, Vega-Benedetti AF, **Ziranu P**, Puzzoni M, Lai E, Faloppi L, Rullán M, Carrascosa J, Amat I, Urman JM, Arechederra M, Berasain C, Ferretti E, Casadei-Gardini A, Avila MA, Alonso S, Scartozzi M, Zavattari P. HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. *Br J Cancer*. 2022 Feb 17. doi: 10.1038/s41416-022-01738-1. Epub ahead of print. PMID: 35177798.
28. Mariani S, Puzzoni M, Giampieri R, **Ziranu P**, Pusceddu V, Donisi C, Persano M, Pinna G, Cimbro E, Parrino A, Spanu D, Pretta A, Lai E, Liscia N, Lupi A, Giglio E, Palomba G, Casula M, Pisano M, Palmieri G and Scartozzi M (2022) Liquid BiopsyDriven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients. *Front. Oncol*. 12:852583. doi: 10.3389/fonc.2022.852583
29. Dubois M, Liscia N, Brunetti O, **Ziranu P**, Lai E, Argentiero A, Mazza E, Cascinu S, Silvestris N, Casadei-Gardini A, Scartozzi M. The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. *Crit Rev Oncol Hematol*. 2022 May;173:103674. doi: 10.1016/j.critrevonc.2022.103674. Epub 2022 Mar 30. PMID: 35364261.
30. V. Aimola, D. Fanni, C. Gerosa, G. Cerrone, **P. Ziranu**, A. Pretta, R. Murrù, M. Piras, F. Cau, L. Zorcolo, G. La Nasa, M. Castagnola, M. Scartozzi, G. Faa. Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer. *Annals of Research in Oncology* Vol. 2(2), 160-166, 2022
31. Pretta A, Spanu D, Mariani S, Liscia N, **Ziranu P**, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E. How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world. *World J Clin Oncol*. 2022 May 24;13(5):417-422. doi: 10.5306/wjco.v13.i5.417. PMID: 35662988; PMCID: PMC9153079.
32. Dario Spanu, Andrea Pretta, Eleonora Lai, Mara Persano, Clelia Donisi, Stefano Mariani, Marco Dubois, Marco Migliari, Giorgio Saba, **Pina Ziranu**, Valeria Pusceddu, Marco Puzzoni, Giorgio Astara, Mario Scartozzi. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment. *World J Hepatol* 2022 July 27; 14(7): 1319-1332
33. Pretta A, Lai E, Donisi C, Spanu D, **Ziranu P**, Pusceddu V, Puzzoni M, Massa E, Scartozzi M. Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? *World J Clin Oncol*. 2022 Dec 24;13(12):980-983. doi: 10.5306/wjco.v13.i12.980. PMID: 36618080; PMCID: PMC9813836.
34. Pretta A, **Ziranu P**, Giampieri R, Donisi C, Cimbro E, Spanu D, Lai E, Pecci F, Balconi F, Lupi A, Pozzari M, Persano M, Murgia S, Pusceddu V, Puzzoni M, Berardi R, Scartozzi M. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. *Dig Liver Dis*. 2023 May;55(5):655-660. doi: 10.1016/j.dld.2022.11.012. Epub 2022 Dec 10. PMID: 36513569.
35. Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco MC, Spada M, Cordio S, Aprile G, Cardellino GG, Maiello E, Bernardini I, Ghidini M, Bozzarelli S, Macchini M, Orsi G, De Simone I, Rulli E, Porcu L, Torri V, Pinto C; GARIBALDI Study Group. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey. *ESMO Open*. 2023 Feb;8(1):100777. doi:

Copy

36. Ziranu P, Pretta A, Pozzari M, Maccioni A, Badiali M, Fanni D, Lai E, Donisi C, Persano M, Gerosa C, Puzzoni M, Bardanzellu F, Ambu R, Pusceddu V, Dubois M, Cerrone G, Migliari M, Murgia S, Spanu D, Pretta G, Aimola V, Balconi F, Murru S, Faa G, Scartozzi M. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. *Sci Rep*. 2023 Mar 16;13(1):4397. doi: 10.1038/s41598-023-26397-4.

37. Basile D, Rosati G, Bergamo F, Garattini SK, Banzi M, Zampino M, Bozzarelli S, Marchetti P, Galli F, Galli F, Longarini R, Zaniboni A, Ferrari D, De Placido S, Frassinetti LG, Nicolini M, Cinieri S, Priscindiaro M, Ziranu P, Caccialanza R, Pastorino A, Mosconi S, Aprile G. Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial. *Clin Colorectal Cancer*. 2023 Jun;22(2):190-198. doi: 10.1016/j.clcc.2023.01.004. Epub 2023 Feb 5. PMID: 36935327.

38. Ziranu P, Aimola V, Pretta A, Dubois M, Murru R, Liscia N, Cau F, Persano M, Deias G, Palmas E, Loi F, Migliari M, Pusceddu V, Puzzoni M, Lai E, Cascinu S, Faa G, Scartozzi M. New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression. *Cancers (Basel)*. 2023 Feb 14;15(4):1212. doi: 10.3390/cancers15041212. PMID: 36831554; PMCID: PMC9953769.

39. Ziranu P, Ferrari PA, Guerrera F, Bertoglio P, Tamburrini A, Pretta A, Lyberis P, Grimaldi G, Lai E, Santoru M, Bardanzellu F, Riva L, Balconi F, Della Beffa E, Dubois M, Pinna-Susnik M, Donisi C, Capozzi E, Pusceddu V, Murenu A, Puzzoni M, Mathieu F, Sarais S, Alzetani A, Luzzi L, Solli P, Paladini P, Ruffini E, Cherchi R, Scartozzi M. Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score. *Lung Cancer*. 2023 Oct;184:107342. doi: 10.1016/j.lungcan.2023.107342.

40. Pretta A, Ziranu P, Giampieri R, Pinna G, Randon G, Donisi C, Ravarino A, Loi F, Deias G, Palmas E, Pretta G, Morano F, Semonella F, Mariani S, Deidda MA, Pusceddu V, Puzzoni M, Lai E, Solinas C, Restivo A, Zorcolo L, Barbara R, Berardi R, Faa G, Pietrantonio F, Scartozzi M. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy. *Br J Cancer*. 2023 Nov;129(10):1619-1624. doi: 10.1038/s41598-023-26397-4.

41. Flaviana Cau, Clara Gerosa, Pina Ziranu, Andrea Pretta, Monica Piras, Matteo Frascini, Peter Van Eyken, Giorgio La Nasa, Massimo Castagnola, Ferdinando Coghe, Germano Orrù, Luigi Zorcolo, Andrei Turtoi, Antonella Balestrieri, Luca Saba, Mario Scartozzi, Gavino Faa. L1cam expression in the peritumoral stromal cells of the microenvironment of colorectal cancer: a new target for oncologists? *Vol. 3 (No. 4) 2023 December; Research Article, 155-164*

42. V. Pusceddu, C. Donisi, A. Pretta, F. Loi, R. Badas, P. Ziranu, M. Puzzoni, E. Lai, S. Mariani, E. Palmas, M. Pozzari, E. Cimbri, A.P. D'Agata, S. Pinto, F. Coghe, S. Bergamini, D. Fanni, G. Faa, T. Yoshino, M. Scartozzi. Immunonutrition supplementation for resectable gastric cancer during standard neoadjuvant chemotherapy of FLOT. A proof-of-concept protocol: I-SUPPLY, *ESMO Gastrointestinal Oncology*, Vo 3, 2024, 100036, ISSN 2949-8198,

43. Corrias G, Lai E, Ziranu P, Mariani S, Donisi C, Liscia N, Saba G, Pretta A, Persano M, Fanni D, Spanu D, Balconi F, Loi F, Deidda S, Restivo A, Pusceddu V, Puzzoni M, Solinas C, Massa E, Madeddu C, Gerosa C, Zorcolo L, Faa G, Saba L, Scartozzi M. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging. *Cancers (Basel)*. 2024 Mar 30;16(7):1364. doi: 10.3390/cancers16071364.

44. Donisi, C.; Pretta, A.; Pusceddu, V.; Ziranu, P.; Lai, E.; Puzzoni, M.; Mariani, S.; Massa, E.; Madeddu, C.; Scartozzi, M. Immunotherapy and Cancer: The Multi-Omics Perspective. *Int. J. Mol. Sci.* **2024**, *25*, 3563. doi: 10.3390/ijms25033563.

45. Lai E, **Ziranu P**, Pezzella F, Pretta A, Liscia N, Hu Z. Editorial: Angiogenesis and access to vasculature as a target in gastrointestinal tumors and predictive biomarkers identification: an open challenge. *Front Oncol*. 2024 May 20;14:1428174.
46. **Ziranu P**, Pretta A, Aimola V, Cau F, Mariani S, D'Agata AP, Codipietro C, Rizzo D, Dell'Utri V, Sanna G, Moleda G, Cadoni A, Lai E, Puzzone M, Pusceddu V, Castagnola M, Scartozzi M, Faa G. CD44: A New Prognostic Marker in Colorectal Cancer? *Cancers (Basel)*. 2024 Apr 19;16(8):1569.
47. Cimbro E, Dessi M, **Ziranu P**, Madeddu C, Atzori F, Lai E, Pretta A, Mariani S, Donisi C, Spanu D, Pozzari M, Murgia S, Saba G, Codipietro C, Palmas E, Sanna G, Semonella F, Sardo S, Finco G, Scartozzi M. Early taxane exposure and neurotoxicity in breast cancer patients. *Support Care Cancer*. 2024 Oct 8;32(10):709.
48. Pretta A, **Ziranu P**, Perissinotto E, Ghelardi F, Marmorino F, Giampieri R, Puci M, De Grandis MC, Lai E, Nasca V, Ciraci P, Puzzone M, Cerma K, Sciortino C, Taravella A, Pretta G, Giuliani L, Damonte C, Pusceddu V, Sotgiu G, Berardi R, Lonardi S, Bergamo F, Pietrantonio F, Cremolini C, Scartozzi M. Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon. *Br J Cancer*. 2025 Feb;132(2):188-194.
49. Faa G, **Ziranu P**, Pretta A, Cau F, Castagnola M, Spanu D, Saba G, D'Agata AP, Tiwari E, Suri JS, Scartozzi M, Saba L. Cancer-associated fibroblasts (CAFs) and plaque-associated fibroblasts (PAFs): Unraveling the cellular crossroads of atherosclerosis and cancer. *Biomed Pharmacother*. 2025 Jul;188:118145.
50. Faa G, **Ziranu P**, Pretta A, Cau R, Coghe F, Cau F, Frascini M, Castagnola M, Saba L, Scartozzi M. The impact of the fetal exposome as a predictor of cancer risk in childhood and adulthood. Aberrant epigenetic events occurring during gestation: May they trigger fetal programming of cancer risk later in life? *Int J Gynaecol Obstet*. 2025 May 20.
51. **Ziranu P**, Pretta A, Saba G, Spanu D, Donisi C, Ferrari PA, Cau F, D'Agata AP, Piras M, Mariani S, Puzzone M, Pusceddu V, Coghe F, Faa G, Scartozzi M. Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions. *Int J Mol Sci*. 2025 Aug 6;26(15):7619. doi: 10.3390/ijms26157619. PMID: 40806747; PMCID: PMC12347742.
52. Pretta A, Nasca V, Marmorino F, Intini R, **Ziranu P**, Randon G, Carullo M, Cerma K, Donisi C, Damonte C, Taravella A, Gaiani C, Pretta G, Pusceddu V, Montroni I, Ciraci P, De Rosa A, Bergamo F, Lonardi S, Cremolini C, Pietrantonio F, Scartozzi M. Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients. *ESMO Open*. 2025 Sep;10(9):105756. doi: 10.1016/j.esmoop.2025.105756. Epub 2025 Sep 1. PMID: 40896878; PMCID: PMC12424413.
53. Gavino Faa, **Pina Ziranu**, Matteo Frascini, Flaviana Cau, Andrea Pretta, Luca Didaci, Peter Van Eyken, Ekta Tiwari, Ferdinando Coghe, Massimo Castagnola, Jasjit S Suri, Yukio Gibo, Luca Saba, Mario Scartozzi, Massimo Rugge. Generative intelligence in precision oncology: Priorities in informatics engineering, pathology and oncology. *Annals of Research in Oncology*. Vol. 5 (No. 3) 2025 September; Review, 130-143; doi: 10.48286/aro.2025.110

**Scientific Publication Peer  
Reviewed Journals without impact  
factor**

1. Carcinoma del colon-retto metastatico. Puzzone M, **Ziranu P**, Demurtas L, Pusceddu V, Scartozzi M. *Omeca*, periodico dell'Ordine dei Medici Chirurghi e degli Odontoiatri della provincia di Cagliari. N° 6 - Giugno 2017
2. Carcinoma del pancreas: la seconda linea Mario Scartozzi, Laura Demurtas, Marco Puzzone, **Pina Ziranu**, *Oncologia Medica*, Azienda Ospedaliero-Universitaria e Università degli Studi di Cagliari, Cagliari. *New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online* N°5, Settembre 2017

3. Carcinoma dello Stomaco. Revisione della letteratura 2017: i 4 lavori più importanti nei tumori dello stomaco. E. Lai, S. Camera, V. Impera, N. Liscia, A.G. Pireddu, A. Pretta, L. Demurtas, M. Puzzone, **P. Ziranu**, M. Scartozzi. *New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online N°4*, Dicembre 2017
4. 2018 GASTROINTESTINAL CANCER SYMPOSIUM–San Francisco CANCERS OF THE ESOPHAGUS AND STOMACH. S. Camera, N. Liscia, AG. Pireddu, M. Persano, F. Musio, S. Mariani, E. Lai, A. Pretta, V. Impera, L. Demurtas, M. Puzzone, **P. Ziranu**, M. Scartozzi. *New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online N°5*, Gennaio 2018
5. 2018 ASCO ANNUAL MEETING- Oral Abstracts Session- Gastrointestinal (Noncolorectal) Cancer- Gastric. A. Pretta, S. Mariani, M. Persano, E. Lai, N. Liscia, V. Impera, AG. Pireddu, V. Pusceddu, M. Puzzone, L. Demurtas, **P. Ziranu**, F. Musio, S. Camera, M. Scartozzi. *New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online N°7*, Giugno 2018
6. ESMO MEETING 2018 – MUNICH: best of gastric cancer presentations. N. Liscia, A. Pretta, M. Persano, V. Impera, S. Tolu, S. Camera, A. Pireddu, F. Musio, S. Mariani, **P. Ziranu**, L. Demurtas, M. Puzzone, V. Pusceddu, E. Lai, M. Scartozzi. *New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online N°8*, Novembre 2018
7. REVISIONE DELLA LETTERATURA 2018: I 4 LAVORI PIU' IMPORTANTI NEI TUMORI DELLO STOMACO. Stefano Mariani, Nicole Liscia, Mara Persano, Simona Tolu, Francesca Balconi, Clelia Donisi, Andrea Pretta Valentino Impera, Silvia Camera, Annagrazia Pireddu, Francesca Musio, Paolo Soro, Valeria Pusceddu, Eleonora Lai, Marco Puzzone, **Pina Ziranu**, Laura Demurtas, Mario Scartozzi. *Oncologia Medica, AOU Cagliari. Università degli Studi di Cagliari. New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online N°9*, Dicembre 2018
8. BEST OF ASCO 2019 - Oral Abstract Sessions - Gastric Cancer. Eleonora Lai, Paolo Soro, Stefano Mariani, Nicole Liscia, Silvia Camera, Mara Persano, Simona Tolu, Clelia Donisi, Francesca Balconi, Valentino Impera, Laura Demurtas, Annagrazia Pireddu, Francesca Musio, Valeria Pusceddu, Andrea Pretta, **Pina Ziranu**, Marco Puzzone, Mario Scartozzi. *New Era Opened Medical Oncology Progress & Perspectives NEOMOPP online N°10*, Giugno 2019
9. Neoplasie dell'esofago. M. Scartozzi, **P. Ziranu**, C.A. Barone. *Manuale di oncologia medica. COMU Collegio degli Oncologi Medici Italiani. Presidente AGLIETTA Massimo. (Cap. 14; pp162- 169) Settembre 2018*

**H- Index: 17**

**Citations: 840**

**ORCID: 0000-0002-5659-7366**

#### **Certificates and other**

Good Clinical Practice training (investigator Version), version #2.0, certificated by Roche/Genentech on 8 Nov 2018

How to publish a scientific paper – Author Workshop -Elsevier Publishing Campus, Dr Jan Willem Wijnen -Executive Publisher – (Maggio 2017 – Cagliari)

Peer Reviewer for: *Cancers*, *Frontiers*, *MDPI*

Editorial Board Member: *Journal of Clinical Oncology and Cancer Therapy*

Corso YOUNG, Young Oncologists Union For Nutrition Goals! (2023), supporto non condizionante di Fresenius Kabi.

patients: overcrowded or straightforward? Elderly patients, unfit.

**26 June 2020 (Cagliari)** Update su nuove strategie nell'immunoterapia dei tumori – Attuali indicazioni cliniche e prospettive dell'immunoterapia dei tumori solidi: Tumori del tratto gastrointestinale.

**26 February 2020 (Cagliari)** Focus on Hepatocellular Carcinoma – Il paziente affetto da epatocarcinoma nella pratica clinica: sequenza terapeutica. Usque tandem?

**20 February 2020 (Vicenza)** News in GI Oncology 2020 – Sessione esofago/stomaco poster review

**17 June 2020 (Macerata)** Tumori gastrointestinali 2.0:2.0 Stato dell'arte e prospettive future – Tumori dello stomaco

**19 November 2019 (Cagliari)** Aggiornamenti 2019 sui Tumori Polmonari (in qualità di Segreteria Scientifica)

**16 October 2019 (Cagliari)** Strategie di trattamento nel paziente mCRC. Terapia del paziente anziano o unfit o BRAF mutato.

**8 October 2019 (Cagliari)** Il Farmaco dalla Ricerca di Base alla Terapia: sinergie tra accademia e impresa realtà e prospettive occupazioni del settore farmaceutico. La Sperimentazione Clinica in Oncologia

**28 June 2019 (Cagliari)** Cure Simultanee a confronto. CURE SIMULTANEE E CARCINOMA GASTRICO: ruolo di ramucirumab

**23-24 May 2019 (Bergamo)** Tumori del Tratto gastrointestinale: tra scienza e pratica. VIII Workshop nazionale

**17 May 2019 (Cagliari)** L'Accademia del Saper fare. Casi clinici in Oncologia

**5-6 April 2019 (Roma)** L'Oncologia Medica di Precisione. Stato dell'arte dell'Immunoterapia nelle malattie Gastrointestinali

**25 January 2019 (Modena):** L'Accademia del Saper Fare. Casi clinici in oncologia Modena

**21 December 2018 (Sassari)** L'algoritmo terapeutico di I linea nei pazienti con mutazioni attivanti dell'EGFR e gestione della resistenza

**23 November 2018 (Nuoro)** Evidenze Scientifiche degli Effetti Positivi dell'Esercizio Fisico in Oncologia

**16 November 2018 (Cagliari)** Convegno regionale SIE -Sezione Sardegna. Complicanze endocrinometaboliche dei nuovi farmaci antitumorali

**8-9 november 2018 (Roma)** Gastro Journal Club - L'importanza della ricerca in Oncologia

**26 September 2018 (Cagliari)** Il gruppo multidisciplinare nella strategia di trattamento del carcinoma del colon-retto

**27 June 2018 (Cagliari)** Il valore del tempo in Oncologia: il carcinoma del colon retto metastatico

**8-9 June 2018 (Santu Lussurgiu)** Innovazione sostenibile e integrazione in oncologia

**19-20 April 2018 (Cuneo)** Immunoterapia 2018: dal tumore gastrico all'epatocarcinoma

**27 November 2017 (Milano)** Carcinoma colo-rettale metastatico (mCRC): gli obiettivi nelle linee di trattamento

**23 October 2017 (Cagliari)** Percorso clinico-assistenziale del paziente con tumore polmonare

**21 October 2017 (Olbia)** Convegno regionale AIOM Sardegna. “Giovani oncologi a confronto su fattori predittivi di risposta: efficacia e applicabilità”

**23 June 2017 (Paulilatino):** Approccio integrato all'epatocarcinoma: quali prospettive?

**12 May 2017 (Cagliari):** L'accademia del Saper fare. Casi clinici in oncologia

**22 November 2016 (Olbia)** L'immunoterapia nel NSCLC: impatto sulla pratica clinica

**01 July 2016 (Cagliari)** I Congresso Regionale F.O.NI.CAP

**27 May 2016 (Cagliari)** Terapia dei tumori solidi: focus su anticorpi monoclonali

**14 May 2016 (Cagliari)** Immunità e Cancro - Convegno Regionale Aiom Giovani Sardegna

**18 April 2016 (Quartu Sant'Elena)** La Rete Delle Cure Palliative: L'Hospice Madonna di Fatima, un'esperienza in atto nel distretto Quartu -Parteolla

**14 April 2015 (Milano)** Nab-paclitaxel o FOLFIRINOX nella strategia terapeutica del carcinoma pancreatico

**13-14 June 2014 (Cagliari)** Congresso Nazionale S.I.C.O.G

**11 January 2014 (Cagliari)** Il tumore del colon-retto: dalla prevenzione al supporto

Personal data use authorized according to the Italian Law D.Lgs 196/03 and art. 13 of GDPR 679/16.

- 30-31 October 2025 (Virtual) - VII Edizione LA RICERCA E LA CURA: UPDATE 2025 Tumori del distretto esofago-gastrico, epato-biliare e tumori rari gastrointestinali. La Ricerca – studio ORACLE**
- 12 December 2024 ADC nel trattamento dell'adenocarcinoma gastrico: il ruolo del Team multidisciplinare - La malattia HER2 positiva: uno scenario in evoluzione**
- 29 November 2024 (Cagliari) 2014..2024: Ten years of Gastrointestinal Oncology: a landscape update in GI cancers – Carcinoma del colon nel 2014 vs 2024**
- 23 November 2024 (Oristano) Oncologia e Oncoematologia in Sardegna – Stato dell'arte e prospettive future – Carcinoma del pancreas: terapia medica nella malattia metastatica**
- 18-19 October 2024 (Cagliari) “XV edizione congresso regionale IAOM Sardegna. Tra novità scientifiche e pratica clinica” in qualità di moderatore della sessione SESSION HCC, BILIARY TRACT AND GASTRIC CANCERS**
- 01 October 2024 (Webinar) Building Bridges to interconnect people – The fully digital meeting in clinical oncology – L'immunoterapia nei tumori gastroesofagei: esiste una nicchia perfetta?**
- 12 July 2024 (Cagliari) Il continuum of care per i pazienti affetti da neoplasia gastro-intestinale - Carcinoma gastrico: è la biologia del tumore o la sequenza terapeutica che fa la differenza?”**
- 21 September 2023 (Milan) - MASTERCLASS Evolution 2.0 in Real Practice - Highlights from Congresses 2023 Focus on GI**
- 23 giugno 2023, (Cagliari) - “Il ruolo di Trifluridina Tipiracil nel percorso terapeutico del paziente con carcinoma del colon retto e carcinoma gastrico oltre la seconda linea”**
- 01 March 2023 (Webinar) Neoplasie gastroenterobiliari complicate da ittero ostruttivo e carcinosi peritoneale: problemi aperti nelle cure simultanee. Terapia medica delle neoplasie digestive: ruolo di Ramucirumab, TAS 102, Lenvatinib, Atezolizumab, Pembrolizumab**
- 28 November 2022 O.P.E.R.A GI (Webinar) Review of targeted therapies for colorectal cancer. From second to multiple lines: the dilemma of choice**
- 24 November 2022 (Webinar): HCC: state of the art in clinical practice”: Dai dati alla pratica clinica**
- 23-24 September 2022 (Cagliari): S'attobiu de Casteddu: Chirurgia up front del tumore (adenocarcinoma) pancreatico, è ancora attuabile? Il chirurgo si confronta con l'oncologo**
- 11 July 2022 (Webinar) 50 minutes on CCA: Diagnostic**
- 15 June 2022 (Milan) Carcinoma gastrico: Nuovi farmaci e nuove strategie terapeutiche**
- 7 April 2022 (Webinar) HCC Frontline combat scelta terapeutica: dalla prima linea alle successive. Scelta delle linee successive. C'è veramente l'imbarazzo della scelta**
- 13 March 2022 (Cagliari) Conoscere e gestire le terapie antitumorali. Vecchi e nuovi farmaci: dalla Struttura Ospedaliera al territorio. Le terapie a bersaglio molecolare: le nuove frontiere dell'oncologia.**
- 18 February 2022 (Cagliari) Il ruolo di trifluridina-tipiracil nel management clinico del paziente con mCRC avanzato**
- 16 February 2022 (Webinar) Integrazione diagnostico-terapeutica, evoluzione dell'arte medica in Oncologia - V Edizione – Epatocarcinoma. Trattamento dell'epatocarcinoma: update e prospettive future**
- Dal 05/11/2021 al 04/11/2022 (FAD Webinar) La gestione degli eventi avversi da inibitori delle tirosinchinasi nell'epatocarcinoma. Stato dell'arte nella gestione del paziente affetto da epatocarcinoma**
- 13-14 October 2021 Young to Young 2021. “Hot topics” di pratica clinica sulle neoplasie gastrointestinali.**
- 05 October 2021 (FAD Webinar) HOT TOPICS in Oncologia 2021: novità dai principali congressi nazionali e internazionali. Le neoplasie gastrointestinali.**
- 11 June 2021 (FAD Webinar): Cure Simultanee: aggiornamento 2021. Regorafenib e immunoterapia: sequenza o combinazione?**
- 10 December 2020 (FAD Webinar) Cure simultanee: aggiornamento 2020. HCC tra comorbilità, coinfezioni e politerapie (I); Cure simultanee e tumori colorettali: ruolo della trifluridina-tipiracil, regorafenib e rechallenge con anti-EGFR (II).**
- 20 November 2020 (FAD Webinar) Upper Gastrointestinal Cancer – Meeting Oncologici Dolomiti – Neoplasia gastrica Trattamento adiuvante e della malattia metastatica (sequenze terapeutiche)**
- 9 September 2020 (FAD Webinar) Multiple treatment lines in metastatica colorectal**